These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16682508)

  • 1. Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ.
    Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu S
    Ann Clin Lab Sci; 2006; 36(2):137-43. PubMed ID: 16682508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.
    Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu SI
    Ann Clin Lab Sci; 2006; 36(1):16-22. PubMed ID: 16501232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.
    Rody A; Diallo R; Poremba C; Speich R; Wuelfing P; Kissler S; Solbach C; Kiesel L; Jackisch C
    Oncol Rep; 2004 Oct; 12(4):695-9. PubMed ID: 15375487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
    van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
    J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
    Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu.
    Diallo R; Rody A; Jackisch C; Ting E; Schaefer KL; Kissler S; Karn T; Geddert H; Engels K; Kaufmann M; Gabbert HE; Shroyer KR; Poremba C
    Hum Pathol; 2006 Feb; 37(2):205-11. PubMed ID: 16426921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different panels of markers should be used to predict mammary Paget's disease associated with in situ or invasive ductal carcinoma of the breast.
    Lester T; Wang J; Bourne P; Yang Q; Fu L; Tang P
    Ann Clin Lab Sci; 2009; 39(1):17-24. PubMed ID: 19201736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors.
    Claus EB; Chu P; Howe CL; Davison TL; Stern DF; Carter D; DiGiovanna MP
    Exp Mol Pathol; 2001 Jun; 70(3):303-16. PubMed ID: 11418009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
    Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
    Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
    Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
    Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG
    Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
    de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
    Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
    Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
    Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
    Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.
    Moinfar F; Okcu M; Tsybrovskyy O; Regitnig P; Lax SF; Weybora W; Ratschek M; Tavassoli FA; Denk H
    Cancer; 2003 Aug; 98(4):703-11. PubMed ID: 12910513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.